,,trastuzumab deruxtecan
daiichi sankyo,daiichi sankyo,astrazeneca,astrazeneca
['destiny,breast,4', 'trastuzumab', 'breast', 'trastuzumab deruxtecan', 'destiny-breast04']
people with her2-low breast cancer may have a new option: trastuzumab deruxtecan. dom's dr. shanu modi shared encouraging results from the phase 3 destiny-breast04 trial at #asco22. #oncology #cancerresearch 
The official account of @MSKCancerCenter’s Department of Medicine. Chair/Dept head @debschrag